Pulmonary Rehabilitation for Advanced Lung Cancer Survivors
This study is for people who have been diagnosed with advanced non-small cell lung cancer (NSCLC) (stages III or IV) and experience shortness of breath. Many lung cancer survivors feel tired and have trouble breathing, which can affect their quality of life. This study is testing if pulmonary rehabilitation (PR), a supportive treatment that includes exercise and education, can help improve these symptoms. You would either receive 8 weeks of PR, given by certified respiratory therapists, or receive standard information about nutrition and physical activity. Researchers will measure changes in your walking ability, how short of breath you feel, and your overall quality of life after 8 weeks. The study aims to enroll 85 participants.
- Study design
- This is an interventional study where participants are randomly assigned to either receive pulmonary rehabilitation or standard care. It plans to enroll 85 participants.
- What's involved
- If you join, you would either attend two pulmonary rehabilitation sessions per week for 8 weeks or receive educational materials. Your functional capacity, breathing, and quality of life will be measured at the beginning and after 8 weeks.
- Compensation
- Not stated in the trial record.
- Follow-up
- Your progress will be measured at the beginning of the study and again after 8 weeks.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
Pulmonary Rehabilitation in Advanced Lung Cancer Survivors
At a glance
Conditions
Where it's being run
1 sites across 1 statesStudy leadership
- Melinda Hsu, MD, MS · PRINCIPAL_INVESTIGATOR · Case Comprehensive Cancer Center, University Hospitals
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
Do you actually qualify for this trial?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Inclusion
Exclusion
What this trial measures
- Change in functional capacity of LCS with advanced NSCLC, as measured by the 6-minute walk test (6MWT)Baseline, 8 weeks
The 6MWT measures the distance (in meters) that a person can walk in 6 minutes, with higher values indicating greater functional capacity
- Change in self-reported dyspnea and quality of life (QoL) in LCS with advanced NSCLC, as measured by the modified Borg scale (MBS)Baseline, 8 weeks
The MBS is a 1-question scale that is asked after the 6MWT, where participants rank their dyspnea (difficulty breathing) on a scale of 1-10, with greater values indicating greater difficulty.
- Change in self-reported dyspnea and quality of life (QoL) in LCS with advanced NSCLC, as measured by the EORTC QLQ-C30Baseline, 8 weeks
The EORTC QLQ-C30 is a 30-question questionnaire that captures functional, symptom, global health status, and QoL domains. Questions are answered on a Likert scale with four choices ranging from "Not at all" to "Very much." Greater scores indicate lower quality of life.
- Change in self-reported dyspnea and quality of life (QoL) in LCS with advanced NSCLC, as measured by the EORTC QLQ-LC29Baseline, 8 weeks
The EORTC QLQ-LC29 is a 29-question questionnaire that captures lung cancer-related symptoms and treatment side effects. Questions are answered on a Likert scale with four choices ranging from "Not at all" to "Very much." Greater scores indicate greater symptoms and side effects.
- Change in quantity of cancer-related adverse events (AEs), as measured by the Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE).Baseline, 8 weeks